Targeting sarcomas: therapeutic targets and their rational

Area of Science:

• Oncology
• Medical Biochemistry
• Molecular Biology

Background:

• Sarcomas are rare, diverse mesenchymal tumors often resistant to conventional chemotherapy.
• Ewing's sarcoma (ES) is a subtype with specific genetic fusions (EWS-FLI1, EWS-ERG) and a plateau in survival rates.
• Cancer stem cells (CSCs) play a role in sarcoma development and present potential therapeutic targets.

Purpose of the Study:

• To review recent advancements in targeted therapy for sarcomas, with a focus on ES.
• To discuss the role of cancer stem cells (CSCs) in sarcoma progression and treatment.
• To highlight the utility of high-throughput proteomic techniques in discovering novel therapeutic targets.

Main Methods:

• Review of current literature on sarcoma targeted therapies.
• Analysis of preclinical and clinical studies on novel drug candidates.
• Exploration of molecular pathways and targets, including tyrosine kinase receptors, mTOR, and HSP90.
• Investigation into the role of cancer stem cells (CSCs) and proteomic data.

Main Results:

• Targeted therapies, including tyrosine kinase inhibitors and mTOR pathway inhibitors, are under clinical evaluation.
• Specific drugs like taxanes, gemcitabine, and ET-743 show efficacy.
• HSP90 inhibitors are identified as relevant targets for ES.
• CSCs represent a promising area for new therapeutic strategies.

Conclusions:

• Targeted therapies offer new hope for treating sarcomas, particularly ES.
• Understanding the role of CSCs and utilizing proteomic data are crucial for developing effective sarcoma treatments.
• Further research into novel molecular targets and therapeutic approaches is warranted.